Key Highlights

  • AtriCure (NASDAQ:ATRC) moved from a USD 0.3 million net loss a year earlier to USD 4.1 million of third-quarter net income, on Revenue of USD 154.5 million, up 15.0%.
  • RxSight (NASDAQ:RXST) carried USD 254.7 million of cash, cash equivalents and short-term investments at September 30, 2026, and its Impairment review concluded long-lived Assets were recoverable.
  • At September 30, 2026, Ceribell (NASDAQ:CBLL) reported USD 117.5 million in cash and marketable securities, and more than 700 hospitals run its system.
  • Philips (NYSE:PHG) posted a 13% group adjusted EBITA margin, 70 basis points higher, and booked a 288 million euro provision on Respironics below that measure.

AtriCure (NASDAQ:ATRC): Scale Economics Tip the Result Positive

AtriCure (NASDAQ:ATRC) went public with its third-quarter 2026 figures on November 3, 2026. Worldwide revenue reached USD 154.5 million, a 15.0% gain, while U.S. revenue climbed 17.1% to USD 128.0 million. Gross Margin landed at 77.3%, up 180 basis points, and operating expenses rose 14% to USD 115.0 million, a pace slower than sales. Operating Income therefore came to USD 4.4 million, and Net Income to USD 4.1 million, or USD 0.08 a share. Adjusted EBITDA jumped 51% to USD 26.8 million. U.S. pain management sales reached USD 28.1 million compared with USD 20.8 million, roughly 35% higher, own arithmetic from the company table. Minimally invasive ablation sales in the U.S. slid to USD 5.4 million from USD 7.4 million as surgeons switched to pulsed field ablation catheters. The 2026 forecast calls for USD 606 to 610 million in revenue and USD 91 to 94 million of adjusted EBITDA. The earlier guidance was absent from the reviewed material, so the size of any change is unknown. Cash stood at USD 187.0 million, against USD 167.4 million at year-end. Competition from catheter-based rivals remains a risk for AtriCure (NASDAQ:ATRC).

RxSight (NASDAQ:RXST): An Impairment Review Alongside USD 254.7 Million of Cash

On November 3, 2026, RxSight (NASDAQ:RXST) filed quarterly results covering the period that ended September 30, 2026. The company flagged possible impairment of its long-lived assets because its market Capitalization had stayed depressed and LDD product volumes had dropped. Management estimated undiscounted future cash flows and compared them with carrying value. Those cash flows exceeded the carrying value, so no impairment charge was booked. An impairment review asks whether expected future cash flows will cover book value, and a write-down, though non-cash, would cut reported Earnings and assets. A securities class action filed July 22, 2025 got past a motion to dismiss on May 21, 2026, and discovery is under way. Allegations are not findings, and the outcome remains open. The company relies on single and sole source suppliers without long-term agreements, and it points to tariffs and Inflation as pressures. The extract did not provide revenue or earnings, so the scale of the slowdown cannot be gauged. A hypothetical 1.00% change in rates would not materially move interest income, and the company calls its foreign currency exposure de minimis.

Ceribell (NASDAQ:CBLL): Hospital Footprint Set Against a USD 280.7 Million Deficit

Ceribell (NASDAQ:CBLL) lodged its Quarterly Report on November 3, 2026, covering the period ended September 30. The company sells a point-of-care electroencephalogram system built from disposable headbands, a pocket-sized recorder and AI-driven algorithms that flag seizures and delirium in acute care. Cash and marketable securities totaled USD 117.5 million, while the accumulated Deficit stood at USD 280.7 million. More than 700 hospitals use the system, out of roughly 6,000 U.S. acute care facilities that management estimates could benefit. FDA clearances came in December 2025, June 2026 and September 2026. Revenue relies on single-use Wearables and monthly subscriptions, so it tracks active accounts and Wearable volume, and the filing notes that intensive care unit patient counts tend to dip in summer. Management believes cash covers at least the next 12 months, while acknowledging that the estimate could prove wrong and more capital may be required. The extract omitted quarterly revenue and net loss, so the Burn Rate cannot be measured, and neither a beat nor a miss can be assigned to Ceribell (NASDAQ:CBLL).

Philips (NYSE:PHG): How a 288 Million Euro Charge Sits Outside the 13% Margin

Philips (NYSE:PHG) unveiled its third-quarter 2026 numbers on November 3, 2026. The adjusted EBITA margin of 13% climbed 70 basis points, helped by higher sales, a better gross margin from newer products, productivity savings and a small Tariff benefit. The 288 million euro provision ties to an agreement in principle with the U.S. Department of Justice over the Sleep and Respiratory Care recall. That amount is booked under adjusting items, which adjusted EBITA leaves out, so the 13% excludes it. Order intake expanded 8%, comparable sales grew about 3%, and free Cash Flow came in at an inflow of 384 million euros. The outlook assumes the settlement is paid during the first quarter of 2027, subject to documentation, and it reaffirms an adjusted EBITA margin of 13.5% to 14%. That range contains a roughly 1% lift from a U.S. tariff refund, which means the underlying margin sits lower. Philips held 2.8 billion euros in cash while carrying 5.4 billion euros of net debt. Other Respironics proceedings, including a State Attorneys General investigation, lie outside the outlook, while China procurement and ultrasound timing are flagged as risks for Philips (NYSE:PHG).

Where Things Stand

The 13% at Philips is an adjusted figure that leaves out a 288 million euro provision, whereas AtriCure's USD 4.1 million is reported net income, so the two cannot be read the same way. Philips (NYSE:PHG) still has to fund the Respironics settlement in the first quarter of 2027. Operating Leverage is visible at AtriCure (NASDAQ:ATRC), even as its minimally invasive ablation sales contract under pulsed field catheter competition. The RxSight (NASDAQ:RXST) extract omits revenue and earnings, which leaves Liquidity and risk disclosures as the only assessable parts. Ceribell (NASDAQ:CBLL) offered the same limits, leaving its burn rate unmeasured. RxSight's impairment test passed and Ceribell says cash lasts 12 months, but both are management views that could shift. Upcoming markers include AtriCure's fourth-quarter delivery against guidance, settlement documents at Philips, litigation rulings at RxSight and any capital raise at Ceribell.